1 week Ago By Defense World Staff
Orion Portfolio Solutions LLC increased its stake in Masimo Co. (NASDAQ:MASI – Free Report) by 2.1% in the 4th quarter, according to the company in its most recent filing with the SEC.
The institutional investor owned 4,778 shares of the medical equipment provider’s stock after acquiring an additional 97 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Masimo were worth $790,000 at the end of the most recent reporting period. A number of other large investors also recently added to or reduced their stakes in the stock.
Vanguard Group Inc. increased its stake in shares of Masimo by 1.5% during the fourth quarter.
Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock worth $758,182,000 after purchasing an additional 66,215 shares in the last quarter. State Street Corp boosted its holdings in Masimo by 0.
7% in the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock worth $191,837,000 after buying an additional 10,179 shares during the last quarter. Geode Capital Management LLC increased its stake in Masimo by 1.
5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after buying an additional 11,984 shares in the last quarter. Charles Schwab Investment Management Inc.
raised its holdings in shares of Masimo by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc.
now owns 377,836 shares of the medical equipment provider’s stock valued at $62,456,000 after acquiring an additional 7,808 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Masimo by 0.
4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider’s stock valued at $61,773,000 after acquiring an additional 1,522 shares in the last quarter.
85.96% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at MasimoIn related news, Director Craig B.
Reynolds sold 2,053 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.
89. Following the completion of the sale, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53.
This trade represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Also, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.
00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28.
The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here.
Company insiders own 9.70% of the company’s stock. Masimo Price PerformanceMasimo stock opened at $144.
40 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.
11 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average price of $173.
64 and a 200 day moving average price of $163.36. Masimo Co.
has a 12-month low of $101.61 and a 12-month high of $194.88.
The stock has a market cap of $7.80 billion, a P/E ratio of 99.59 and a beta of 1.
28. Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.
80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38.
Masimo had a net margin of 3.85% and a return on equity of 14.98%.
The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million.
Sell-side analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current year.
Analyst Upgrades and DowngradesSeveral research firms recently commented on MASI. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Piper Sandler increased their target price on shares of Masimo from $210.
00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Raymond James boosted their price target on shares of Masimo from $170.
00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company raised their target price on shares of Masimo from $193.
00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company.
According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $194.80.
View Our Latest Research Report on MasimoMasimo Profile (Free Report)Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.See AlsoFive stocks we like better than MasimoWhat is a Bond Market Holiday? How to Invest and TradeNewsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?The Risks of Owning BondsDisney 2025 Shareholders: Major Updates for Investors3 Warren Buffett Stocks to Buy NowAdvance Auto Parts Stock: A Classic Rebound Play in the MakingWant to see what other hedge funds are holding MASI? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI – Free Report)..
